Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options. A recent article discussing the company reads, “Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs, which already have proof-of-concept data supporting clinical use in their selected indications. The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa: acquires drugs that already have some clinical data to support the targeted treatment; navigates through the FDA, collaborating with the reviewers to define a complete development program; and develops each drug over the course of 2-5 years, out-licensing either just prior to pivotal study, after Phase 2b or after the completion of the pivotal study.”
To view the full article, visit https://ibn.fm/q7Xvu
About Processa Pharmaceuticals Inc.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions — medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and board of directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
